Septerna (SEPN) Competitors $22.50 -1.70 (-7.02%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends SEPN vs. IMVT, OGN, IBRX, RYTM, APLS, MLTX, HCM, AGIO, DYN, and VRNAShould you be buying Septerna stock or one of its competitors? The main competitors of Septerna include Immunovant (IMVT), Organon & Co. (OGN), ImmunityBio (IBRX), Rhythm Pharmaceuticals (RYTM), Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), HUTCHMED (HCM), Agios Pharmaceuticals (AGIO), Dyne Therapeutics (DYN), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry. Septerna vs. Immunovant Organon & Co. ImmunityBio Rhythm Pharmaceuticals Apellis Pharmaceuticals MoonLake Immunotherapeutics HUTCHMED Agios Pharmaceuticals Dyne Therapeutics Verona Pharma Septerna (NASDAQ:SEPN) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk. Do analysts prefer SEPN or IMVT? Septerna presently has a consensus price target of $43.67, suggesting a potential upside of 94.07%. Immunovant has a consensus price target of $48.10, suggesting a potential upside of 83.80%. Given Septerna's higher possible upside, equities research analysts clearly believe Septerna is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Immunovant 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SEPN or IMVT more profitable? Septerna's return on equity of 0.00% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A Immunovant N/A -56.40%-52.03% Which has better earnings & valuation, SEPN or IMVT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepternaN/AN/AN/AN/AN/AImmunovantN/AN/A-$259.34M-$2.22-11.79 Does the media prefer SEPN or IMVT? In the previous week, Septerna had 13 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Septerna and 1 mentions for Immunovant. Immunovant's average media sentiment score of 0.90 beat Septerna's score of 0.64 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 1 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer SEPN or IMVT? Immunovant received 118 more outperform votes than Septerna when rated by MarketBeat users. However, 100.00% of users gave Septerna an outperform vote while only 78.21% of users gave Immunovant an outperform vote. CompanyUnderperformOutperformSepternaOutperform Votes4100.00% Underperform VotesNo VotesImmunovantOutperform Votes12278.21% Underperform Votes3421.79% Do institutionals and insiders hold more shares of SEPN or IMVT? 47.1% of Immunovant shares are held by institutional investors. 5.9% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummarySepterna and Immunovant tied by winning 5 of the 10 factors compared between the two stocks. Ad Behind the Markets📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Get Septerna News Delivered to You Automatically Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEPN vs. The Competition Export to ExcelMetricSepterna IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02B$2.08B$5.01B$8.81BDividend YieldN/A15.15%5.16%4.06%P/E RatioN/A10.69134.3717.77Price / SalesN/A167.751,158.6875.18Price / CashN/A92.1133.5332.53Price / BookN/A1.484.674.68Net IncomeN/A$70.32M$119.07M$226.08M7 Day Performance0.54%1.01%-1.83%-1.04%1 Month PerformanceN/A0.74%-3.62%1.04%1 Year PerformanceN/A14.89%31.63%26.28% Septerna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEPNSepternaN/A$22.50-7.0%$43.67+94.1%N/A$1.02BN/A0.00N/AAnalyst ForecastNews CoverageGap UpIMVTImmunovant1.5467 of 5 stars$26.17+3.8%$48.10+83.8%-22.6%$3.84BN/A-11.79120OGNOrganon & Co.4.7217 of 5 stars$14.73+0.9%$21.33+44.9%+31.6%$3.76B$6.26B2.9210,000IBRXImmunityBio0.735 of 5 stars$4.88-8.8%$4.75-2.6%+20.4%$3.73B$620,000.000.00590Positive NewsRYTMRhythm Pharmaceuticals2.8994 of 5 stars$59.36-1.0%$62.30+5.0%+78.0%$3.69B$77.43M0.00140Analyst ForecastAPLSApellis Pharmaceuticals4.5973 of 5 stars$27.49-5.2%$51.06+85.7%-44.5%$3.42B$396.59M-13.54702MLTXMoonLake Immunotherapeutics3.2708 of 5 stars$49.82+1.0%$79.00+58.6%+16.8%$3.18BN/A-38.622HCMHUTCHMED1.1549 of 5 stars$17.96+7.2%$20.55+14.4%-3.1%$3.13B$838M0.001,988Analyst DowngradeNews CoverageGap UpAGIOAgios Pharmaceuticals3.3113 of 5 stars$54.62+0.4%$52.33-4.2%+154.0%$3.10B$32.87M4.81390DYNDyne Therapeutics3.3858 of 5 stars$29.99+1.0%$51.40+71.4%+181.6%$3.05BN/A-8.42100Insider TradeAnalyst RevisionVRNAVerona Pharma2.5968 of 5 stars$38.85+2.0%$43.83+12.8%+163.7%$3.04B$460,000.000.0030Positive News Related Companies and Tools Related Companies IMVT Competitors OGN Competitors IBRX Competitors RYTM Competitors APLS Competitors MLTX Competitors HCM Competitors AGIO Competitors DYN Competitors VRNA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SEPN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Septerna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Septerna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
